Novavax (NVAX) Cost of Revenue (2011 - 2026)

Novavax's Cost of Revenue history runs 10 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 117.46% year-over-year to $30.7 million; the TTM figure through Mar 2026 stood at $89.6 million (down 43.15% YoY), while the FY2025 annual figure was $73.0 million, down 63.97% from the prior year.
• Cost of Revenue for Q1 2026 stood at $30.7 million, up from $22.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $434.6 million in Q3 2022, with the low at $14.1 million in Q1 2025.
• The 5-year median for Cost of Revenue is $46.2 million (2024), against an average of $91.3 million.
• Peak annual rise in Cost of Revenue reached 124.19% in 2023, while the deepest fall reached 79.42% in 2023.
• Novavax's Cost of Revenue stood at $181.8 million in 2022, then slipped by 14.74% to $155.0 million in 2023, then plunged by 76.34% to $36.7 million in 2024, then slumped by 39.72% to $22.1 million in 2025, then surged by 38.87% to $30.7 million in 2026.
• Business Quant data shows NVAX's Cost of Revenue at $30.7 million in Q1 2026, $22.1 million in Q4 2025, and $21.5 million in Q3 2025.